- Home
- GLTO vs FMST Comparison
GLTO vs FMST Comparison
Compare GLTO & FMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- FMST
- Stock Information
- Founded
- GLTO 2011
- FMST 2005
- Country
- GLTO Denmark
- FMST Canada
- Employees
- GLTO N/A
- FMST N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- FMST Other Metals and Minerals
- Sector
- GLTO Health Care
- FMST Basic Materials
- Exchange
- GLTO Nasdaq
- FMST Nasdaq
- Market Cap
- GLTO 6.5M
- FMST 7.1M
- IPO Year
- GLTO 2020
- FMST N/A
- Fundamental
- Price
- GLTO $2.83
- FMST $0.83
- Analyst Decision
- GLTO Buy
- FMST
- Analyst Count
- GLTO 1
- FMST 0
- Target Price
- GLTO $10.00
- FMST N/A
- AVG Volume (30 Days)
- GLTO 719.8K
- FMST 53.7K
- Earning Date
- GLTO 03-19-2025
- FMST 01-01-0001
- Dividend Yield
- GLTO N/A
- FMST N/A
- EPS Growth
- GLTO N/A
- FMST N/A
- EPS
- GLTO N/A
- FMST N/A
- Revenue
- GLTO N/A
- FMST N/A
- Revenue This Year
- GLTO N/A
- FMST N/A
- Revenue Next Year
- GLTO N/A
- FMST N/A
- P/E Ratio
- GLTO N/A
- FMST N/A
- Revenue Growth
- GLTO N/A
- FMST N/A
- 52 Week Low
- GLTO $2.79
- FMST $0.55
- 52 Week High
- GLTO $19.75
- FMST $3.48
- Technical
- Relative Strength Index (RSI)
- GLTO 38.47
- FMST 44.52
- Support Level
- GLTO $2.79
- FMST $0.76
- Resistance Level
- GLTO $3.38
- FMST $0.85
- Average True Range (ATR)
- GLTO 0.77
- FMST 0.08
- MACD
- GLTO -0.17
- FMST 0.02
- Stochastic Oscillator
- GLTO 2.88
- FMST 54.62
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.